private:topicapharmaceuticals
|
828526
|
Mar 9th, 2018 12:00AM
|
Topica Pharmaceuticals
|
113
|
2.00
|
Open
|
Pharmaceuticals
|
Mar 8th, 2018 11:12PM
|
Mar 8th, 2018 11:12PM
|
|
Open
|
|
|
|
|
|
|
|
|
Topica Pharmaceuticals
|
Oil & Gas
|
Pharmaceuticals & Biotechnology
|
private:topicapharmaceuticals
|
828526
|
Feb 17th, 2018 12:00AM
|
Topica Pharmaceuticals
|
113
|
2.00
|
Open
|
Pharmaceuticals
|
Feb 17th, 2018 02:25PM
|
Feb 17th, 2018 02:25PM
|
Topica Pharmaceuticals, Inc. is a privately held pharmaceutical company focused on the clinical development of luliconazole for onychomycosis. Onychomycosis or nail fungus affects 32M patients in the US today. Due to the limitations of currently approved FDA treatments it is estimated that less than 3M patients receive treatment for this disease. T Topica holds an exclusive license for luliconazole in the America's and Europe. Luliconazole is currently approved in Japan where it is the leading topical prescription antifungal. In 2010 Topica sublicensed its luliconazole program for tinea infections (fungal infections of the skin) to Medicis, which has since been acquired by Valeant Pharmaceuticals. Valeant has filed an NDA for 1% luliconazole cream which is currently in review by the FDA with approval expected in late 2013. Luliconazole is the most potent antifungal molecule known against the most common fungal pathogens that cause nail fungus. Luliconazole is approximately 60 x more potent than the most potent treatment currently approved for onychomycosis (oral terbinafine). Topica's 10% Luliconazole Solution is currently being studied in a 334 patient phase 2b/3 trial that completed enrollment in June 13. Study results are expected in Q3'14. In a positive data scenario Topica will be seeking a partner for US and EU development and commercialization.
|
|
|
|
|
|
|
|
|
|
Topica Pharmaceuticals
|
Oil & Gas
|
Pharmaceuticals & Biotechnology
|
private:topicapharmaceuticals
|
828526
|
Feb 16th, 2018 12:00AM
|
Topica Pharmaceuticals
|
113
|
2.00
|
Open
|
Pharmaceuticals
|
Feb 16th, 2017 08:15AM
|
Feb 16th, 2017 08:15AM
|
Topica Pharmaceuticals, Inc. is a privately held pharmaceutical company focused on the clinical development of luliconazole for onychomycosis. Onychomycosis or nail fungus affects 32M patients in the US today. Due to the limitations of currently approved FDA treatments it is estimated that less than 3M patients receive treatment for this disease. T
Topica holds an exclusive license for luliconazole in the America's and Europe. Luliconazole is currently approved in Japan where it is the leading topical prescription antifungal. In 2010 Topica sublicensed its luliconazole program for tinea infections (fungal infections of the skin) to Medicis, which has since been acquired by Valeant Pharmaceuticals. Valeant has filed an NDA for 1% luliconazole cream which is currently in review by the FDA with approval expected in late 2013.
Luliconazole is the most potent antifungal molecule known against the most common fungal pathogens that cause nail fungus. Luliconazole is approximately 60 x more potent than the most potent treatment currently approved for onychomycosis (oral terbinafine). Topica's 10% Luliconazole Solution is currently being studied in a 334 patient phase 2b/3 trial that completed enrollment in June 13. Study results are expected in Q3'14. In a positive data scenario Topica will be seeking a partner for US and EU development and commercialization.
|
|
|
|
|
|
|
|
|
|
Topica Pharmaceuticals
|
Oil & Gas
|
Pharmaceuticals & Biotechnology
|
private:topicapharmaceuticals
|
828526
|
Feb 15th, 2018 12:00AM
|
Topica Pharmaceuticals
|
113
|
2.00
|
Open
|
Pharmaceuticals
|
Feb 15th, 2017 10:07AM
|
Feb 15th, 2017 10:07AM
|
Topica Pharmaceuticals, Inc. is a privately held pharmaceutical company focused on the clinical development of luliconazole for onychomycosis. Onychomycosis or nail fungus affects 32M patients in the US today. Due to the limitations of currently approved FDA treatments it is estimated that less than 3M patients receive treatment for this disease. T
Topica holds an exclusive license for luliconazole in the America's and Europe. Luliconazole is currently approved in Japan where it is the leading topical prescription antifungal. In 2010 Topica sublicensed its luliconazole program for tinea infections (fungal infections of the skin) to Medicis, which has since been acquired by Valeant Pharmaceuticals. Valeant has filed an NDA for 1% luliconazole cream which is currently in review by the FDA with approval expected in late 2013.
Luliconazole is the most potent antifungal molecule known against the most common fungal pathogens that cause nail fungus. Luliconazole is approximately 60 x more potent than the most potent treatment currently approved for onychomycosis (oral terbinafine). Topica's 10% Luliconazole Solution is currently being studied in a 334 patient phase 2b/3 trial that completed enrollment in June 13. Study results are expected in Q3'14. In a positive data scenario Topica will be seeking a partner for US and EU development and commercialization.
|
|
|
|
|
|
|
|
|
|
Topica Pharmaceuticals
|
Oil & Gas
|
Pharmaceuticals & Biotechnology
|
private:topicapharmaceuticals
|
828526
|
Feb 14th, 2018 12:00AM
|
Topica Pharmaceuticals
|
113
|
2.00
|
Open
|
Pharmaceuticals
|
Feb 14th, 2017 01:50PM
|
Feb 14th, 2017 01:50PM
|
Topica Pharmaceuticals, Inc. is a privately held pharmaceutical company focused on the clinical development of luliconazole for onychomycosis. Onychomycosis or nail fungus affects 32M patients in the US today. Due to the limitations of currently approved FDA treatments it is estimated that less than 3M patients receive treatment for this disease. T
Topica holds an exclusive license for luliconazole in the America's and Europe. Luliconazole is currently approved in Japan where it is the leading topical prescription antifungal. In 2010 Topica sublicensed its luliconazole program for tinea infections (fungal infections of the skin) to Medicis, which has since been acquired by Valeant Pharmaceuticals. Valeant has filed an NDA for 1% luliconazole cream which is currently in review by the FDA with approval expected in late 2013.
Luliconazole is the most potent antifungal molecule known against the most common fungal pathogens that cause nail fungus. Luliconazole is approximately 60 x more potent than the most potent treatment currently approved for onychomycosis (oral terbinafine). Topica's 10% Luliconazole Solution is currently being studied in a 334 patient phase 2b/3 trial that completed enrollment in June 13. Study results are expected in Q3'14. In a positive data scenario Topica will be seeking a partner for US and EU development and commercialization.
|
|
|
|
|
|
|
|
|
|
Topica Pharmaceuticals
|
Oil & Gas
|
Pharmaceuticals & Biotechnology
|
private:topicapharmaceuticals
|
828526
|
Feb 13th, 2018 12:00AM
|
Topica Pharmaceuticals
|
113
|
2.00
|
Open
|
Pharmaceuticals
|
Feb 13th, 2017 04:11PM
|
Feb 13th, 2017 04:11PM
|
Topica Pharmaceuticals, Inc. is a privately held pharmaceutical company focused on the clinical development of luliconazole for onychomycosis. Onychomycosis or nail fungus affects 32M patients in the US today. Due to the limitations of currently approved FDA treatments it is estimated that less than 3M patients receive treatment for this disease. T
Topica holds an exclusive license for luliconazole in the America's and Europe. Luliconazole is currently approved in Japan where it is the leading topical prescription antifungal. In 2010 Topica sublicensed its luliconazole program for tinea infections (fungal infections of the skin) to Medicis, which has since been acquired by Valeant Pharmaceuticals. Valeant has filed an NDA for 1% luliconazole cream which is currently in review by the FDA with approval expected in late 2013.
Luliconazole is the most potent antifungal molecule known against the most common fungal pathogens that cause nail fungus. Luliconazole is approximately 60 x more potent than the most potent treatment currently approved for onychomycosis (oral terbinafine). Topica's 10% Luliconazole Solution is currently being studied in a 334 patient phase 2b/3 trial that completed enrollment in June 13. Study results are expected in Q3'14. In a positive data scenario Topica will be seeking a partner for US and EU development and commercialization.
|
|
|
|
|
|
|
|
|
|
Topica Pharmaceuticals
|
Oil & Gas
|
Pharmaceuticals & Biotechnology
|
private:topicapharmaceuticals
|
828526
|
Feb 12th, 2018 12:00AM
|
Topica Pharmaceuticals
|
113
|
2.00
|
Open
|
Pharmaceuticals
|
Feb 12th, 2017 04:15AM
|
Feb 12th, 2017 04:15AM
|
Topica Pharmaceuticals, Inc. is a privately held pharmaceutical company focused on the clinical development of luliconazole for onychomycosis. Onychomycosis or nail fungus affects 32M patients in the US today. Due to the limitations of currently approved FDA treatments it is estimated that less than 3M patients receive treatment for this disease. T
Topica holds an exclusive license for luliconazole in the America's and Europe. Luliconazole is currently approved in Japan where it is the leading topical prescription antifungal. In 2010 Topica sublicensed its luliconazole program for tinea infections (fungal infections of the skin) to Medicis, which has since been acquired by Valeant Pharmaceuticals. Valeant has filed an NDA for 1% luliconazole cream which is currently in review by the FDA with approval expected in late 2013.
Luliconazole is the most potent antifungal molecule known against the most common fungal pathogens that cause nail fungus. Luliconazole is approximately 60 x more potent than the most potent treatment currently approved for onychomycosis (oral terbinafine). Topica's 10% Luliconazole Solution is currently being studied in a 334 patient phase 2b/3 trial that completed enrollment in June 13. Study results are expected in Q3'14. In a positive data scenario Topica will be seeking a partner for US and EU development and commercialization.
|
|
|
|
|
|
|
|
|
|
Topica Pharmaceuticals
|
Oil & Gas
|
Pharmaceuticals & Biotechnology
|
private:topicapharmaceuticals
|
828526
|
Feb 11th, 2018 12:00AM
|
Topica Pharmaceuticals
|
113
|
2.00
|
Open
|
Pharmaceuticals
|
Feb 11th, 2017 05:35AM
|
Feb 11th, 2017 05:35AM
|
Topica Pharmaceuticals, Inc. is a privately held pharmaceutical company focused on the clinical development of luliconazole for onychomycosis. Onychomycosis or nail fungus affects 32M patients in the US today. Due to the limitations of currently approved FDA treatments it is estimated that less than 3M patients receive treatment for this disease. T
Topica holds an exclusive license for luliconazole in the America's and Europe. Luliconazole is currently approved in Japan where it is the leading topical prescription antifungal. In 2010 Topica sublicensed its luliconazole program for tinea infections (fungal infections of the skin) to Medicis, which has since been acquired by Valeant Pharmaceuticals. Valeant has filed an NDA for 1% luliconazole cream which is currently in review by the FDA with approval expected in late 2013.
Luliconazole is the most potent antifungal molecule known against the most common fungal pathogens that cause nail fungus. Luliconazole is approximately 60 x more potent than the most potent treatment currently approved for onychomycosis (oral terbinafine). Topica's 10% Luliconazole Solution is currently being studied in a 334 patient phase 2b/3 trial that completed enrollment in June 13. Study results are expected in Q3'14. In a positive data scenario Topica will be seeking a partner for US and EU development and commercialization.
|
|
|
|
|
|
|
|
|
|
Topica Pharmaceuticals
|
Oil & Gas
|
Pharmaceuticals & Biotechnology
|
private:topicapharmaceuticals
|
828526
|
Feb 10th, 2018 12:00AM
|
Topica Pharmaceuticals
|
113
|
2.00
|
Open
|
Pharmaceuticals
|
Feb 10th, 2017 06:43AM
|
Feb 10th, 2017 06:43AM
|
Topica Pharmaceuticals, Inc. is a privately held pharmaceutical company focused on the clinical development of luliconazole for onychomycosis. Onychomycosis or nail fungus affects 32M patients in the US today. Due to the limitations of currently approved FDA treatments it is estimated that less than 3M patients receive treatment for this disease. T
Topica holds an exclusive license for luliconazole in the America's and Europe. Luliconazole is currently approved in Japan where it is the leading topical prescription antifungal. In 2010 Topica sublicensed its luliconazole program for tinea infections (fungal infections of the skin) to Medicis, which has since been acquired by Valeant Pharmaceuticals. Valeant has filed an NDA for 1% luliconazole cream which is currently in review by the FDA with approval expected in late 2013.
Luliconazole is the most potent antifungal molecule known against the most common fungal pathogens that cause nail fungus. Luliconazole is approximately 60 x more potent than the most potent treatment currently approved for onychomycosis (oral terbinafine). Topica's 10% Luliconazole Solution is currently being studied in a 334 patient phase 2b/3 trial that completed enrollment in June 13. Study results are expected in Q3'14. In a positive data scenario Topica will be seeking a partner for US and EU development and commercialization.
|
|
|
|
|
|
|
|
|
|
Topica Pharmaceuticals
|
Oil & Gas
|
Pharmaceuticals & Biotechnology
|
private:topicapharmaceuticals
|
828526
|
Feb 9th, 2018 12:00AM
|
Topica Pharmaceuticals
|
113
|
2.00
|
Open
|
Pharmaceuticals
|
Feb 9th, 2017 08:57AM
|
Feb 9th, 2017 08:57AM
|
Topica Pharmaceuticals, Inc. is a privately held pharmaceutical company focused on the clinical development of luliconazole for onychomycosis. Onychomycosis or nail fungus affects 32M patients in the US today. Due to the limitations of currently approved FDA treatments it is estimated that less than 3M patients receive treatment for this disease. T
Topica holds an exclusive license for luliconazole in the America's and Europe. Luliconazole is currently approved in Japan where it is the leading topical prescription antifungal. In 2010 Topica sublicensed its luliconazole program for tinea infections (fungal infections of the skin) to Medicis, which has since been acquired by Valeant Pharmaceuticals. Valeant has filed an NDA for 1% luliconazole cream which is currently in review by the FDA with approval expected in late 2013.
Luliconazole is the most potent antifungal molecule known against the most common fungal pathogens that cause nail fungus. Luliconazole is approximately 60 x more potent than the most potent treatment currently approved for onychomycosis (oral terbinafine). Topica's 10% Luliconazole Solution is currently being studied in a 334 patient phase 2b/3 trial that completed enrollment in June 13. Study results are expected in Q3'14. In a positive data scenario Topica will be seeking a partner for US and EU development and commercialization.
|
|
|
|
|
|
|
|
|
|
Topica Pharmaceuticals
|
Oil & Gas
|
Pharmaceuticals & Biotechnology
|